Retinoic acid p-hydroxyanilide, >=95%

Application

Retinoic acid p-hydroxyanilide has been used: as a synthetic retinoid to induce apoptosis in SEB-1 sebocytesas a medium supplement for C2C12 myoblasts to test its effect on ceramide formation to test in cytotoxicity in T-cellacute lymphoblastic leukemia (T-ALL)

Biochem/physiol Actions

Retinoic acid p-hydroxyanilide, also called fenretinide, increases reactive oxygen species, activates caspases and induces apoptosis. It also inhibits dihydroceramide desaturase, leading to a decrease in ceramide biosynthesis. Fenretinide may elicit anticancer activity in cultured human breast cancer cells. It acts as an insulin antagonist and may be useful in treating insulin resistance. Fenretinide or 4-HPR has chemotherapeuticpotential and is cytotoxic to retinoic acid-resistant cancers.

Vitamin A acid analogue with antiproliferative activity; induces apoptosis in malignant hemopoietic cell lines.

General description

Retinoic acid p-hydroxyanilide is a synthetic analog of retinoid.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. H7779.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

5 mg in glass bottle